Champix is a varenicline-based medicine for adults who want to stop smoking. It helps reduce nicotine cravings and withdrawal symptoms by partially stimulating nicotine receptors while making cigarettes less rewarding.
Champix is a smoking-cessation treatment containing varenicline in film-coated tablets. It is intended for adults who want to stop smoking and need help reducing nicotine cravings and withdrawal symptoms. Varenicline acts on nicotine receptors in the brain, making smoking less rewarding while easing the urge to smoke.
Champix contains varenicline, a selective partial agonist of the α4β2 nicotinic acetylcholine receptor. Each film-coated tablet contains 1 mg of varenicline, and the pack contains 56 tablets.
Varenicline is not nicotine replacement therapy. It does not provide nicotine to the body. Instead, it partially stimulates the brain receptors normally activated by nicotine from cigarettes. This produces a modest dopamine response that can reduce irritability, restlessness, low mood, and strong smoking urges during withdrawal.
Champix is taken by mouth with water. The tablets may be taken with or without food, though taking them after a meal can reduce nausea for some people.
The dose is stated on the pack — follow the leaflet.
If a dose is missed, take it when remembered unless the next dose is close. Do not take two doses together to make up for a missed tablet. Taking extra varenicline is more likely to increase nausea, dizziness, or sleep-related adverse effects.
The dose is stated on the pack — follow the leaflet. People with severe kidney impairment may need a lower dose because varenicline is largely eliminated through the kidneys. The FDA prescribing information also advises dose adjustment for severe renal impairment. [2]
Smoking activates nicotinic receptors and releases dopamine, reinforcing the smoking habit. Varenicline attaches strongly to the same receptors. It activates them less intensely than nicotine while blocking much of nicotine’s effect if a cigarette is smoked.
This dual action matters. Cravings may become more manageable because the receptors still receive limited stimulation. Smoking can also feel less satisfying because nicotine cannot bind as effectively. The EMA describes varenicline as a partial agonist at α4β2 nicotinic receptors, which explains why it differs from nicotine patches, gum, or lozenges. [1]
The medicine does not remove every urge immediately. Smoking is linked to routines such as coffee breaks, driving, stress, and social situations. Varenicline addresses the physical dependence component, while planning for these cues addresses the behavioural component. A quit plan supports this process. Behavioural support can help people practise alternative responses.
Champix is a smoking-cessation treatment containing varenicline in 1 mg film-coated tablets. It is intended for adults who want to stop smoking and need help reducing nicotine cravings and withdrawal symptoms.
Champix targets nicotine receptors directly, while nicotine replacement supplies controlled nicotine and bupropion works through noradrenaline and dopamine pathways.
| Approach | Main mechanism | Practical distinction |
|---|---|---|
| Varenicline | Partial agonist at α4β2 nicotine receptors | Reduces cravings and can make smoking less rewarding |
| Nicotine replacement therapy | Replaces nicotine without cigarette smoke | Helps withdrawal symptoms but still supplies nicotine |
| Bupropion | Alters noradrenaline and dopamine signalling | May suit some adults, but seizure risk and interaction concerns limit use |
Varenicline is often selected when cravings are intense, previous nicotine replacement therapy did not achieve abstinence, or smoking remains rewarding despite attempts to cut down. Nicotine replacement can be useful for people who prefer a non-tablet approach or need flexible short-term dosing around cravings.
Bupropion may be considered in selected cases, yet it is unsuitable for people with seizure disorders, bulimia, anorexia nervosa, or certain interacting medicines. A 2023 Cochrane review found high-certainty evidence that varenicline improves long-term quit rates compared with placebo and suggests it may outperform single-form nicotine replacement therapy. [3]
Varenicline has few major metabolic drug interactions because it is not extensively processed by liver enzymes. Still, stopping smoking can change the body’s handling of medicines such as theophylline, warfarin, insulin, clozapine, and olanzapine. Their doses may need review as tobacco smoke exposure falls.
Champix is not for you if you have had a serious allergic reaction to varenicline or any component of the tablets.
Nausea is the most common adverse effect with Champix. It is often mild to moderate and tends to be strongest during the first weeks. Other common effects include headache, insomnia, unusual dreams, constipation, gas, indigestion, dizziness, fatigue, and dry mouth.
Vivid dreams are a distinctive complaint. They are not always unpleasant, but some people find them disruptive. Taking the evening dose earlier, rather than immediately before bed, may help without changing the total daily regimen.
Stop taking varenicline and seek urgent medical assessment for swelling of the face or throat, severe rash or blistering, chest pain, fainting, new seizures, or marked changes in behaviour. Depression, agitation, hostility, suicidal thoughts, or suicidal behaviour require prompt clinical attention, especially in people with a history of psychiatric illness.
Smoking cessation itself can affect mood, sleep, concentration, and appetite. These symptoms may come from nicotine withdrawal, the medicine, or both. The WHO tobacco-cessation guideline recognises varenicline as a pharmacological option alongside behavioural support, with treatment choice guided by medical history and patient preference. [4]
Alcohol deserves special attention. Some people have reported increased intoxication, memory gaps, or unusual behaviour while taking varenicline. Limiting or avoiding alcohol during the first weeks can show whether individual tolerance changes.
Several avoidable patterns reduce the benefit of Champix:
One mistake deserves extra emphasis: do not crush, split, or chew the film-coated tablets. The tablet should be swallowed whole to ensure the intended dose is taken properly.
In clinical practice, smoking-cessation clinicians often see the best results when Champix is paired with a specific quit date and a written plan for predictable triggers. Tablets can reduce the biological pull of nicotine, but they do not automatically change the habit of reaching for a cigarette after meals or during stressful calls.
Doctors also set realistic expectations. Cravings may still appear, especially in the first two weeks after stopping. The useful difference is that a craving often becomes shorter and less compelling, giving the person time to use a planned response.
A lapse does not always mean treatment has failed. One cigarette should be treated as information about a trigger, not as a reason to abandon the quit attempt. NICE recommends behavioural support alongside pharmacotherapy for tobacco dependence because medicine and structured support address different parts of dependence. [5]
Champix is usually started one to two weeks before the planned quit date so varenicline can begin occupying nicotine receptors before cigarettes are stopped. Some people notice cigarettes becoming less satisfying during the first week, while withdrawal cravings are usually assessed after the quit date. The EMA product information from 2021 describes the gradual titration period as part of the standard treatment schedule.
Champix can be taken with or without food. Taking each tablet after a meal with a full glass of water is often more comfortable for people who develop nausea. The FDA label from 2021 lists nausea as a common adverse effect and supports dose reduction in selected patients when tolerability is poor.
Champix does not contain nicotine. Its active ingredient, varenicline, works by partially stimulating and blocking nicotine-sensitive receptors in the brain. This differs from nicotine gum, patches, sprays, and lozenges, which provide measured nicotine doses. The Cochrane review published in 2023 evaluates varenicline separately from nicotine replacement therapy because their mechanisms differ.
Alcohol may affect people differently during treatment with varenicline. Reduced alcohol tolerance, unusual behaviour, aggression, and memory gaps have been reported, so alcohol should be limited until individual response is clear. The FDA included this warning in its 2021 prescribing information for varenicine.
Past depression or anxiety does not automatically rule out treatment, but mood history needs careful consideration before starting. New agitation, depressed mood, suicidal thinking, or marked behavioural changes need urgent clinical assessment during treatment. The WHO tobacco-cessation guideline published in 2024 supports evidence-based cessation medicines while recognising the value of individual clinical assessment.
A cigarette during treatment does not erase progress. Varenicline may reduce the rewarding effect of nicotine, and the lapse can help identify a trigger such as alcohol, stress, driving, or social pressure. Continuing the planned regimen and strengthening the response to that trigger is usually more useful than treating the lapse as failure. NICE guidance from 2021 places relapse prevention and behavioural support alongside pharmacological treatment.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
I had smoked for nearly 20 years. The first week brought nausea after the morning tablet, but taking it after breakfast fixed most of it. By the quit date, cigarettes still crossed my mind, yet the urge passed faster than before.
The dreams were extremely vivid during the second week. Moving my evening dose to dinner helped. I had one cigarette at a family gathering, then went back to my plan instead of giving up.
I noticed less satisfaction when I tried to smoke. The difficult part was not nicotine; it was the habit of smoking while driving. I kept sugar-free gum in the car and that made a real difference.
Nausea and poor sleep were too much for me at first. I had been taking the tablets without food and late at night. After changing the timing, sleep improved, though I still needed a review because of ongoing anxiety.
